* Better Therapeutics Inc BTTX.OQ BTTX.O is expected
to show
no change in quarterly revenue when it reports results on May
11.
*
* Refinitiv's mean analyst estimate for Better Therapeutics
Inc
is for a loss of 74 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Better
Therapeutics Inc is $10, above its last closing price
of $0.80.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.51 -0.37 Beat 27
Sep. 30 2022 -0.44 -0.48 -0.48 Met -0.7
Jun. 30 2022 -0.46 -0.45 -0.42 Beat 6.7
Mar. 31 2022 -0.40 -0.38 -0.41 Missed -6.5
Dec. -0.47 -0.46 -0.71 Missed -55.5
31 2021
Sep. 30 2021 -1.66 -1.66 -0.03 Beat 98.2
This summary was machine generated May 9 at 12:58 GMT. All
figures in US dollars unless otherwise stated